Results 191 to 200 of about 29,286 (231)

Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia: A Case Report. [PDF]

Cureus
Izadian Bidgoli A, Gomez Veliz A, Yazdanpanah S, Saavedra G, Pina A, Rame G.   +5 more
europepmc   +1 more source

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment. [PDF]

iScience
Rebecca VW, Xiao M, Kossenkov A, Godok T, Brown GS, Fingerman D, Alicea GM, Wei M, Ji H, Portuallo M, Bravo J, Elad V, Chen Y, Toska E, Fane ME, Couts KL, Villanueva J, Nathanson K, Arun KM, Warrier G, Yin X, Ding J, Liu Q, Goyal Y, Gopal YNV, Davies MA, Herlyn M.   +26 more
europepmc   +1 more source

Dasatinib and Quercetin Alleviate Retinal Ganglion Cell Dendritic Shrinkage and Promote Axonal Regeneration in Mice with Optic Nerve Injury. [PDF]

Int J Mol Sci
Bin X, Zhou S, Xu Y, Chen S, Chen S, Yao W, Cao Y, Qiu K, Ng TK.   +8 more
europepmc   +1 more source

Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. [PDF]

Clin Cancer Res
Yoshimura S, Li Y, Inoue S, Meyer CT, Yang X, Du G, Hsiao YC, Li Z, Yang W, Hu J, Andersen CL, Saygin C, Karol SE, Bernt KM, Yu J, Stock W, Teachey DT, Konopleva M, Yang JJ.   +18 more
europepmc   +1 more source

Cellular senescence and metabolic aging in type 2 diabetes: mechanistic insights and translational implications. [PDF]

Front Endocrinol (Lausanne)
Syed AR, Aloti RA, Awad BJ, Alghoul WII, Hassan MAMSA, Kharoufeh A, Rangraze I.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dasatinib

Reactions Weekly, 2009
Dasatinib is an orally available short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI). It potently inhibits BCR-ABL and SRC family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and PDGFR-β, and ephrin receptor kinase. Dasatinib is an effective treatment for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute ...
Markus, Lindauer, Andreas, Hochhaus
  +9 more sources

Dasatinib

Reactions Weekly, 2014
Dasatinib (Sprycel®), a second-generation TKI, has been shown to be effective as an anticancer drug in the treatment of patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib. Several methods of gefitinib synthesis are included in this review.
Hesham M, Korashy, A F M Motiur, Rahman, Mohammed Gabr, Kassem   +2 more
  +5 more sources

Dasatinib

BioDrugs, 2012
Susan J Keam, Keam Susan J
exaly   +3 more sources

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation

Blood, 2011
Dasatinib is a novel, potent, ATP-competitive inhibitor of Bcr-Abl, cKIT, and Src family kinases that exhibits efficacy in patients with imatinib-resistant chronic myelogenous leukemia.
Alexandra Mazharian, Cedric Ghevaert, Steffen Masberg   +2 more
exaly   +3 more sources